Silgard -Drug Insights, 2017 [Report Updated: 30-05-2017]

Published by Delve Insight: 30 May 2017 | 83964

Sorry, this report is no longer available.

We may have other suitable reports available - try Searching for Silgard
or contact our sales team for personal assistance: phone +44 (0) 1305 753769 or email office@sectorpublishing.com.

Introduction

DelveInsight Drug Report, “Silgard- Drug Insights, 2017” highlights the Silgard marketed details, pipeline status and the Global API Manufacturers along with the location. The DelveInsight’s report covers the Global Market Assessment of the Silgard covering the total sales estimation and also provides the Silgard sales performance during the historical period and forecast period to 2018. DelveInsight’s Report also covers the detailed clinical assessment of Silgard, patents information and exclusivity data, route of synthesis, competitive landscape, and generic players. In addition to this, DelveInsight’s Report provides the SWOT analysis for the Silgard.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated drug.

Scope

• A review of the Silgard based on information derived from company and industry-specific sources

• Coverage of the Marketed data of the Silgard on the basis of MOA, target, dosage, route of administration, molecule type, strength, Chemical type and ATC Classification

• Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and API Manufactures in China & India for Silgard with location details

• Patent Expiry Timeline and Exclusivity Details

• Route of Synthesis of the API

• Global Forecasted Sales Figure to 2018

• Qualitative and quantitative assessment of market space

• SWOT Analysis

Reasons to buy

• Evaluate the marketing status and exclusivity details of Silgard to exploit opportunities for generic drug development opportunities.

• Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Silgard.

• API intelligence over Silgard and gaining primary intelligence over Active Ingredients manufacturers across the globe.

• Understanding the chemical route of synthesis of Silgard.

• Uncovering opportunities in the rapidly growing the US market

• Stay ahead of competition by understanding the changing competitive landscape

• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

• Make more informed business decisions from insightful and in-depth analysis of the drug’s performance

• Obtain sales forecast for currently marketed drug for to 2018

Table of Contents
for Silgard -Drug Insights, 2017 [Report Updated: 30-05-2017]

List Of Tables
in Silgard -Drug Insights, 2017 [Report Updated: 30-05-2017]

• Table 1: Silgard, Historical Global Sales (in million USD), 2017

• Table 2: Silgard, Forecasted Global Sales (in million USD), 2017

• Table 3: Silgard, Description

• Table 4: Silgard, Marketed Details the United States (US)

• Table 5: Silgard, Marketed Details the Europe (EU)

• Table 6: Silgard, Patent/Exclusivity Expiry (Year), 2017

• Table 7: Silgard, Patent Number Specific Patent Expiry (Year), 2017

• Table 8: Silgard, Patent Details

• Table 9: Silgard, Route of Synthesis

• Table 10: Silgard, the United States Drug Master File (US DMF), 2017

• Table 11: Silgard, the Europe Active Substance Master File (ASMF), 2017

• Table 12: Silgard, the API Manufacturers, China, 2017

• Table 13: Silgard, the API Manufacturers, India, 2017

• Table 14: Silgard, Generic Players, 2017

• Table 15: Silgard, Pipeline Drug Details, 2017

• Table 16: Silgard, Clinical Trials, 2017

• Table 17: Silgard, Clinical Trials by Zone, 2017

• Table 18: Company Overview, 2017

• Table 19: Silgard, SWOT Analysis, 2017

List Of Figures, Charts and Diagrams
in Silgard -Drug Insights, 2017 [Report Updated: 30-05-2017]

• Figure 1: Silgard, Historical Global Sales (in million USD), 2017

• Figure 2: Silgard, Forecasted Global Sales (in million USD), 2017

• Figure 3: Silgard, Patent/Exclusivity Expiry (Year), 2017

• Figure 4: Silgard, Patent Number Specific Patent Expiry (Year), 2017

• Figure 5: Silgard, Route of synthesis

• Figure 6: Silgard, the API Manufacturers by the US DMF Status (%), 2017

• Figure 7: Silgard, the API Manufacturers by Region, 2017

• Figure 8: Silgard, the API Manufacturers by Location/Countries, 2017

• Figure 9: Silgard, Generic Players, 2017

• Figure 10: Silgard, Clinical Trials by Zone (%), 2017

Additional Details

Publisher

Delve Insight

Publisher Information

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.



We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Reference

83964 | DIDR2017188

Number of Pages

35

Report Format

PDF

Delve Insight Reports

This report is published by Delve Insight

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data